THY1 and breast carcinoma: Thus, we assessed cell invasiveness in a Matrigel assay and found that treatment with Thy-1-Fc enhanced invasion of breast cancer cells, compared to TRAIL-R2-Fc-treated or NS controls (Figure 1C).